ABO2011 for advanced solid tumors (phase 1/2)
Treatments studied
Part of Cancer clinical trials.
This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has been confirmed by a biopsy or tissue sample, and it has either spread or cannot be surgically removed.
- You have tried at least one standard cancer treatment that didn't work for you, or you cannot have those treatments.
- You are generally active and able to take care of yourself (ECOG status 0 or 1).
- You have at least one tumor that can be injected with the study drug and can be biopsied.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new medicine (ABOD2011) in people with advanced solid tumors that have come back or spread after standard treatment. It may help by shrinking tumors and allows researchers to study the tumor by giving medicine directly into it and taking a biopsy.
This trial is testing a new drug, SHR-A2102, either alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests two new drugs, JS212 and JS213, alone or together, for people with certain advanced cancers that have stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.
This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug called toripalimab. The vaccine is designed specifically for your tumor and may help your body's immune system fight cancer better after surgery or standard treatment.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.